drugset / Trial / NCT03912428

Novel PET Radioligand as an Inflammatory Biomarker in Musculoskeletal Conditions

NCT03912428

Phase 1 Terminated 31 enrolled National Institute of Mental Health (NIMH)
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

Background: Inflammation plays a significant role in various disorders that involve neurodegeneration or autoimmune reaction as one of their mechanisms. PET scans can help detect inflammation. Two new drugs may create better PET images. Objective: \- To see if the drug \[11C\]MC1 can help image inflammation. Eligibility: * People age 18 and older with rheumatoid arthritis or idiopathic inflammatory myopathy (IIM). * Healthy volunteers enrolled in protocol 01-M-0254 or 17-M-0181 are also needed. Design: * Healthy participants will be screened under protocol 01-M-0254 or 17-M-0181. * Participants with arthritis or IIM will have a screening visit. This will include: * Medical history * Physical exam * Blood and urine tests * Possible CT or X-ray: A machine will take pictures of the body. * Healthy participants will have 1 or 2 visits. They may have urine tests. They may take the drug celecoxib by mouth. They will have a PET scan. A small amount of one or both study drugs will be injected through a catheter: A needle will guide a thin plastic tube into an arm vein. Another catheter will draw blood. They will like on a bed that slides into a machine. Their vital signs and heart activity will be measured. * Participants with arthritis will have up to 2 visits after screening. They may take celecoxib and have PET scans. * Participants with IIM will have up to 3 visits after screening. At 1 or 2 visits, they will take celecoxib and have PET scans. They will have 1 visit where they have an MRI: They will lie on a table that slides into a machine. The machine takes pictures of the body.

Timeline

Start
2019-06-14
Primary completion
2024-06-14
Completion
2024-06-14

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject 11C-ER176 Diagnostic / imaging agent 15 mbq
Subject 11C-MC1 Diagnostic / imaging agent 10 mbq Intravenous
Subject 11C-MC1 Diagnostic / imaging agent 15 mbq Intravenous
Subject 11C-MC1 Diagnostic / imaging agent 20 mbq Intravenous
Subject Celecoxib Other / unclassified 200 mg Oral
Subject Celecoxib Other / unclassified 400 mg Oral
Subject Celecoxib Other / unclassified 600 mg Oral